Clinical trials: Heart Failure (HF)
Heart Failure With Preserved Ejection Fraction (HFpEF
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve.
- Trial name
- Rebalance-HF (NCT04592445)
- Testing
- Greater Splanchnic Nerve Ablation
- Where
- 26 sites in United States, Georgia
- Volunteers
- 150 people
- Sponsor
- Axon Therapies, Inc.
Heart Disease, Heart Failure
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial.
- Conditions
- Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic
- Trial name
- PHRASE-HF (NCT06675552)
- Where
- 6 sites in Germany
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Heart Failure, Congestive
PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure
The purpose of this study is to determine the value of diagnostic data obtained from Medtronic implantable cardioverter defibrillators (ICDs) with cardiac resynchronization therapy (CRT) to evaluate cardiovascular and heart…
- Trial name
- NCT00279955
- Testing
- Cardiac Resynchronization Therapy Device
- Where
- 93 sites in United States
- Volunteers
- 1,024 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
- Trial name
- NCT06991257
- Testing
- Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Where
- 150 sites in United States, Argentina and 12 more
- Volunteers
- 620 people
- Sponsor
- Pfizer
Acute Decompensated Heart Failure
Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)
To access the efficacy of intravenous (IV) administration of CD-NP on changes in cardiac output and wedge pressure in patients with stabilized acute heart failure
- Trial name
- PreCONDITION (NCT00699712)
- Testing
- CD-NP (Chimeric natriuretic peptide)
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Nile Therapeutics
Cardiac Output, Low
Cardiac Output Autonomic Stimulation Therapy for Heart Failure (COAST-HF) - Human NeuroCatheter Study
A single-center feasibility study in patients undergoing cardiac catheterization, to investigate the acute hemodynamic effects of transvenous cardiac autonomic nerve stimulation.
- Trial name
- COAST-HF HNrCS (NCT02880683)
- Testing
- NeuroTronik CANS Therapy System
- Where
- Paraguay
- Volunteers
- 16 people
- Sponsor
- NeuroTronik Inc.
Heart Failure, Acute Heart Failure
PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days…
- Trial name
- NCT03161158
- Testing
- CHIARA-System, Usual care IV diuretics
- Where
- 11 sites in Germany, Sweden
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Heart Failure
RESpiration deTection From Implanted Cardiac Devices in Subjects With Heart Failure (REST-HF)
The purpose of this prospective, non-randomized, single-arm, research study is to evaluate the accuracy of acutely extracting respiratory rate and tidal volume from implanted cardiac device impedance in subjects with heart…
- Trial name
- REST-HF (NCT03087084)
- Testing
- Cardiac Pacing and Impedance Measurement system
- Where
- 3 sites in Belgium, South Africa
- Volunteers
- 25 people
- Sponsor
- Medtronic BRC
Heart Failure With Reduced Ejection Fraction
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF).
- Trial name
- SALVADOR-HF (NCT06831825)
- Testing
- YAP101 (AAV9-Sav-shRNA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medley Therapeutics
Anemia, Cardiovascular Disease
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial).
- Conditions
- Anemia, Cardiovascular Disease, Congestive Heart Failure, Heart Failure
- Trial name
- NCT00534456
- Testing
- Darbepoetin alfa
- Volunteers
- 12 people
- Sponsor
- Amgen
Heart Failure NYHA Class III
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III
This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).
- Trial name
- PROACTIVE-HF (NCT04089059)
- Testing
- Cordella™ Pulmonary Artery Sensor System
- Where
- 74 sites in United States, Belgium and 1 more
- Volunteers
- 738 people
- Sponsor
- Endotronix, Inc.
Heart Failure
OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network
Patients suffering from heart failure and a markedly reduced pumping capacity and sometimes desynchronization of the lower chambers of the heart have a higher risk of suffering sudden cardiac death.
- Trial name
- OptiLink-HF (NCT00769457)
- Testing
- Access Arm
- Where
- Germany
- Volunteers
- 1,002 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Reducing Lung CongestIon Symptoms in Advanced Heart Failure
The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association…
- Trial name
- RELIEVE-HF (NCT03499236)
- Testing
- V-Wave Interatrial Shunt, Control
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 605 people
- Sponsor
- V-Wave Ltd
Heart Diseases, Cardiovascular Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Heart Failure
- Trial name
- EvolutionHF-DE (NCT06336330)
- Where
- 47 sites in Germany
- Volunteers
- 831 people
- Sponsor
- AstraZeneca
Heart Failure
Evaluating Mobile Health Tool Use for Capturing Patient-centered Outcomes Measures in HF Patients
Heart Failure (HF) is a highly prevalent disease that also carries high morbidity and mortality. The Food and Drug Administration (FDA) recognizes the importance of developing patient-centric endpoints that are relevant to…
- Trial name
- NCT04191356
- Where
- 6 sites in United States, Singapore
- Volunteers
- 67 people
- Sponsor
- Biofourmis Singapore Pte Ltd.
Chronic Heart Failure
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.
- Trial name
- RELAX-REPEAT (NCT01982292)
- Testing
- RLX030 (serelaxin)
- Where
- 52 sites in United States, Australia and 11 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Heart Failure
REDUCE LAP-HF III Corvia Protocol 1701
This is a post market trial to be conducted at sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System…
- Trial name
- REDUCELAPHFIII (NCT03191656)
- Testing
- IASD Implant
- Where
- 27 sites in Germany, Switzerland
- Volunteers
- 500 people
- Sponsor
- Corvia Medical
Heart Failure, Ischemic Heart Failure
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
- Conditions
- Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
- Trial name
- EMERALD (NCT07347197)
- Testing
- HS-005
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Heartseed Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Extended IASD Investigation: REDUCE LAP-HF IV
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients…
- Trial name
- NCT04632160
- Testing
- IASD System II
- Sponsor
- Corvia Medical